Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9926
Peer-review started: May 21, 2021
First decision: July 15, 2021
Revised: August 2, 2021
Accepted: September 19, 2021
Article in press: September 19, 2021
Published online: November 16, 2021
Processing time: 172 Days and 12.4 Hours
We report three patients with drug-induced gingiva overgrowth (DIGO) caused by nifedipine, a calcium channel blocker, who were treated and followed up for 1–3 years. We discussed their symptoms, treatment process, treatment prognosis, and follow-up results.
All the patients had a history of nifedipine treatment to control hypertension. Besides nifedipine, Patient 1 was prescribed immunosuppressant cyclosporine A to control nephritis, which is also implicated in GO. Thus, we assumed that a synergistic effect between the drugs contributed to the severity of Patient 1’s condition. This condition has been reported to be more pronounced in patients with periodontitis. In the course of treatment, Patients 1 and 2 did not stop or change drugs. After initial periodontal treatment, periodontal surgery, and later periodontal support and better plaque control, their gingival hyperplasia was well managed and controlled. Under the guidance of a physician, Patient 3 replaced her calcium-channel blocker drug with losartan potassium and hydrochloro
Patients’ compliance, self-plaque control, and professional periodontal therapy have a vital role in treating and preventing the recurrence of DIGO.
Core Tip: Our data suggest that initial periodontal therapy and replacing drugs may be useful for treating drug-induced gingival overgrowth (DIGO) in patients with heavy periodontitis and mild GO. For those patients who cannot replace medications, basic periodontal treatment, periodontal surgery, and timely and effective periodontal maintenance therapy can also be used to treat and prevent a recurrence. Patients’ compliance, self-plaque control, and professional periodontal therapy have a vital role in treating and preventing the recurrence of DIGO.